Nebivolol Winning Pitch Concepts

This launch and pre-launch pitch work helped win an important antihypertensive account for S&H while I was ECD there. Nebivolol was a late-to-the-party beta blocker with unique vasodilatory properties that enabled it to effectively open blood vessels and lower blood pressure—regardless of age or race. Making it appropriate therapy for more patients than ever. Lovista was a name we created for the pitch. The product is still handled by S&H and marketed under the brand name Bystolic.